EVALUATION OF SERUM PERIOSTIN AND PIIINP AS BIOMARKERS OF RENAL FIBROSIS AND FUNCTION DECLINE IN RENAL TRANSPLANT PATIENTS

Sanja Stanković, Branka Mitić, Andriana Jovanović, Vladana Stoiljković, Nikola Stefanović, Valentina N. Nikolic

DOI Number
https://doi.org/10.22190/FUMB240710006S
First page
Last page

Abstract


This study aimed to evaluate the potential of serum periostin and N-terminal propeptide of type III procollagen (PIIINP) as biomarkers for predicting renal fibrosis and functional decline in renal transplant patients. We conducted a two-visit observational study among 86 renal allograft patients, reduced to 35 at the two-year follow-up due to the COVID-19 pandemic. Blood samples were collected at baseline and follow-up, while urine samples were collected only at follow-up. Serum levels of PIIINP and periostin were measured using ELISA kits, and various renal function parameters were assessed. Serum PIIINP levels showed a significant decrease over two years (p<0.001, Wilcoxon test), while periostin levels significantly increased (p<0.001, Wilcoxon test). These changes correlated with declines in renal function, as indicated by decreased serum albumin and creatinine clearance levels, and increased serum creatinine levels. Significant correlations were found between changes in PIIINP and creatinine clearance (Spearman coefficient = 0.352, p<0.05), as well as between changes in periostin and creatinine clearance (Spearman coefficient = 0.626, p<0.001). Our findings suggest that serum periostin and PIIINP levels are valuable biomarkers for assessing renal fibrosis and functional decline in renal transplant patients. These biomarkers may provide insights into disease progression and guide therapeutic interventions.

 


Keywords

renal fibrosis, kidney transplant, chronic allograft nephropathy (CAN), biomarkers, periostin, N-terminal propeptide of type III procollagen (PIIINP), renal function decline

Full Text:

PDF

References


Reiss AB, Jacob B, Zubair A, Srivastava A, Johnson M, De Leon J. Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets. J Clin Med. 2024;13(7):1881.

Linkermann A, Green D. R. Necroptosis and renal fibrosis: A link to chronic kidney disease? Nat Rev Nephrol. 2019; 15(6):324-326.

Djudjaj S, Boor P. Cellular and molecular mechanisms of kidney fibrosis. Molecular aspects of medicine. 2019; 65:16-36.

Hewitson TD. Fibrosis in the kidney: is a problem shared a problem halved? Fibrogenesis Tissue Repair. 2012; 5(Suppl 1):S14.

Vanhove T, Goldschmeding R, Kuypers D. Kidney Fibrosis: Origins and Interventions. Transplantation. 2017;101(4):713-726.

Saritas T, Kramann R. Kidney allograft fibrosis: Diagnostic and therapeutic strategies. Transplantation. 2021;105(10):e114-30.

Langewisch E, Mannon RB. Chronic Allograft Injury. Clin J Am Soc Nephrol. 2021; 16(11):1723-1729.

Riella LV, Djamali A, Pascual J. Chronic allograft injury: Mechanisms and potential treatment targets. Transplant Rev (Orlando). 2017; 31(1):1-9.

Bansal N, Carpenter MA, Weiner DE, et al. Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial. J Am Soc Nephrol. 2016; 27(7):2109-21.

Teppo AM, Törnroth T, Honkanen E, Grönhagen-Riska C. Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients. Transplantation. 2003; 75(12):2113-9.

Bentata Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs. 2020; 44(2):140-152.

Ghoul BE, Squalli T, Servais A, et al. Urinary procollagen III aminoterminal propeptide (PIIINP): a fibrotest for the nephrologist. Clin J Am Soc Nephrol. 2010; 5(2):205-10.

Heickendorff L, Zachariae H, Bjerring P, Halkier-Sørensen L, Søndergaard K. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. J Am Acad Dermatol. 1995; 32(4):584-8.

Turczyn A, Pańczyk-Tomaszewska M. The role of periostin in kidney diseases. Central European Journal of Immunology. 2021; 46(4):494-501.

Mael-Ainin M, Abed A, Conway SJ, Dussaule JC, Chatziantoniou C. Inhibition of periostin expression protects against the development of renal inflammation and fibrosis. J Am Soc Nephrol. 2014; 25(8):1724-36.

Zhang Y, Dai Y, Raman A, Daniel E, Metcalf J, Reif G, Pierucci-Alves F, Wallace DP. Overexpression of TGF-β1 induces renal fibrosis and accelerates the decline in kidney function in polycystic kidney disease. American Journal of Physiology-Renal Physiology. 2020 Dec 1;319(6): F1135-48.

Kavvadas P, Dussaule JC, Chatziantoniou C. Searching novel diagnostic markers and targets for therapy of CKD. Kidney Int Suppl. 2014; 4(1):53-57.

Prakoura N, Chatziantoniou C. Periostin and Discoidin Domain Receptor 1: New Biomarkers or Targets for Therapy of Renal Disease. Front Med (Lausanne). 2017; 4:52.

Zhang Y, Reif G, Wallace DP. Extracellular matrix, integrins, and focal adhesion signaling in polycystic kidney disease. Cellular signalling. 2020; 72:109646.




DOI: https://doi.org/10.22190/FUMB240710006S

Refbacks

  • There are currently no refbacks.


© University of Niš, Serbia
Creative Commons licence CC BY-NC-ND
ISSN 0354-4699 (Print)
ISSN 2406-050X (Online)